AAV Purification Using Polydiallyldialkylammonium Salt Flocculation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying adeno-associated virus (AAV) from aqueous biomass are inefficient in removing AAV-helper viruses, which are necessary for safety and quality control, especially in large-scale production for clinical use.
Innovation Solution
The use of polydiallyldialkylammonium salts, such as polydiallyldimethylammonium chloride (pDADMAC), to form aggregates with AAV-helper viruses, allowing for their selective removal from the biomass, followed by further purification using chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chromatography, viral clearance filters and heat inactivation are used to remove AAV-helper viruses, then the safety and purity of AAV product is improved, but the process complexity and cost increase
Solution Approach 1:
The patent extracts and removes AAV-helper viruses from the aqueous biomass using polydiallyldialkylammonium salts, which selectively bind to and precipitate the helper viruses. This extraction approach eliminates the need for multiple complex purification steps including chromatography, viral clearance filters, and heat inactivation, thereby reducing process complexity while maintaining safety and purity requirements
Solution Approach 2:
The patent changes the chemical parameters of the system by introducing polydiallyldialkylammonium salts, which alter the electrochemical properties of the solution to enable selective precipitation of AAV-helper viruses. This parameter change allows for simplified removal of contaminants without requiring multiple complex process steps
2Reliability
If multiple purification steps are used to ensure safety and quality, then the purity of AAV product is improved, but the production time and cost increase
Solution Approach 1:
The patent performs extraction of AAV-helper viruses in a single step using polydiallyldialkylammonium salts, replacing multiple sequential purification steps. This consolidation dramatically reduces production time while achieving the required purity levels through selective binding and precipitation of contaminant viruses
Solution Approach 2:
The patent performs preliminary removal of AAV-helper viruses early in the purification process using polydiallyldialkylammonium salts, which simplifies subsequent processing steps. This preliminary action eliminates the need for multiple later purification steps, reducing overall production time while ensuring quality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively reduces AAV-helper virus titers by 2-3 logs without affecting AAV titers, enhancing the purity and safety of the AAV product for clinical use.
Implementation Method 1
contacting the biomass with polydiallyldialkylammonium salt to form an aggregate and a clarified solution, wherein the aggregate comprises the AAV-helper virus
Data Source
AI summary
The invention relates to methods of selectively purifying an adeno-associated virus (AAV) from an aqueous biomass using a flocculent. In embodiments, the flocculent is polydiallyldialkylammonium salt, e.g., polydiallyldimethvlammonium chloride (pDADMAC).